» Articles » PMID: 21368230

Plasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes

Overview
Journal J Immunol
Date 2011 Mar 4
PMID 21368230
Citations 226
Authors
Affiliations
Soon will be listed here.
Abstract

Regulatory T cells (Tregs) constitute an attractive therapeutic target given their essential role in controlling autoimmunity. However, recent animal studies provide evidence for functional heterogeneity and lineage plasticity within the Treg compartment. To understand better the plasticity of human Tregs in the context of type 1 diabetes, we characterized an IFN-γ-competent subset of human CD4(+)CD127(lo/-)CD25(+) Tregs. We measured the frequency of Tregs in the peripheral blood of patients with type 1 diabetes by epigenetic analysis of the Treg-specific demethylated region (TSDR) and the frequency of the IFN-γ(+) subset by flow cytometry. Purified IFN-γ(+) Tregs were assessed for suppressive function, degree of TSDR demethylation, and expression of Treg lineage markers FOXP3 and Helios. The frequency of Tregs in peripheral blood was comparable but the FOXP3(+)IFN-γ(+) fraction was significantly increased in patients with type 1 diabetes compared to healthy controls. Purified IFN-γ(+) Tregs expressed FOXP3 and possessed suppressive activity but lacked Helios expression and were predominately methylated at the TSDR, characteristics of an adaptive Treg. Naive Tregs were capable of upregulating expression of Th1-associated T-bet, CXCR3, and IFN-γ in response to IL-12. Notably, naive, thymic-derived natural Tregs also demonstrated the capacity for Th1 differentiation without concomitant loss of Helios expression or TSDR demethylation.

Citing Articles

Diabetes mellitus, metformin's target gene AMPK, and inflammatory bowel disease: A Mendelian randomization study.

Wu W, Tong H, Li Y, Cui J Medicine (Baltimore). 2025; 104(7):e41532.

PMID: 39960958 PMC: 11835072. DOI: 10.1097/MD.0000000000041532.


CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity.

Kong Y, Li J, Zhao X, Wu Y, Chen L Front Immunol. 2025; 15():1519671.

PMID: 39850899 PMC: 11754230. DOI: 10.3389/fimmu.2024.1519671.


CD137-expressing regulatory T cells in cancer and autoimmune diseases.

Lee K, Mei Y, Liu H, Schwarz H Mol Ther. 2024; 33(1):51-70.

PMID: 39668561 PMC: 11764688. DOI: 10.1016/j.ymthe.2024.12.010.


The 'T paradox' in inflammatory arthritis.

Schnell J, Briviesca R, Kim T, Charbonnier L, Henderson L, van Wijk F Nat Rev Rheumatol. 2024; 21(1):9-21.

PMID: 39653758 DOI: 10.1038/s41584-024-01190-w.


Sphingosine-1-Phosphate Signalling Inhibition Suppresses Th1-Like Treg Generation by Reversing Mitochondrial Uncoupling.

Coulombeau R, Selck C, Giang N, Al-Mohammad A, Ng N, Maher A Immunology. 2024; 174(1):153-166.

PMID: 39444366 PMC: 11652410. DOI: 10.1111/imm.13870.


References
1.
Bonecchi R, Bianchi G, Bordignon P, DAmbrosio D, Lang R, Borsatti A . Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998; 187(1):129-34. PMC: 2199181. DOI: 10.1084/jem.187.1.129. View

2.
Zheng Y, Chaudhry A, Kas A, deRoos P, Kim J, Chu T . Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature. 2009; 458(7236):351-6. PMC: 2864791. DOI: 10.1038/nature07674. View

3.
Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S, Liebenberg V . Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res. 2009; 69(2):599-608. DOI: 10.1158/0008-5472.CAN-08-2361. View

4.
Riley J, June C, Blazar B . Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity. 2009; 30(5):656-65. PMC: 2742482. DOI: 10.1016/j.immuni.2009.04.006. View

5.
OShea J, Paul W . Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science. 2010; 327(5969):1098-102. PMC: 2997673. DOI: 10.1126/science.1178334. View